Nuvation Bio [NUVB] vs Recursion [RXRX] Detailed Stock Comparison

Nuvation Bio Inc.

NYSE
Loading...

Recursion Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Nuvation Bio Inc. wins in 11 metrics, Recursion Pharmaceuticals Inc. wins in 7 metrics, with 0 ties. Nuvation Bio Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Nuvation Bio Inc. Recursion Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A -2.44 N/A
Price-to-Book Ratio 5.81 1.64 Recursion Pharmaceuticals Inc.
Debt-to-Equity Ratio 21.90 6.89 Recursion Pharmaceuticals Inc.
PEG Ratio -35.31 0.04 Recursion Pharmaceuticals Inc.
EV/EBITDA -6.23 -2.10 Recursion Pharmaceuticals Inc.
Profit Margin (TTM) 85.22% 4.45% Nuvation Bio Inc.
Operating Margin (TTM) -81.30% -328.80% Nuvation Bio Inc.
Return on Equity -53.18% -59.54% Nuvation Bio Inc.
Return on Assets (TTM) -23.46% -27.72% Nuvation Bio Inc.
Free Cash Flow (TTM) $-181.78M $-380.44M Nuvation Bio Inc.
1-Year Return 125.47% -14.11% Nuvation Bio Inc.
Price-to-Sales Ratio (TTM) 28.30 24.83 Recursion Pharmaceuticals Inc.
Enterprise Value $1.32B $1.19B Nuvation Bio Inc.
EV/Revenue Ratio 20.94 15.88 Recursion Pharmaceuticals Inc.
Gross Profit Margin (TTM) 96.94% 59.62% Nuvation Bio Inc.
Revenue per Share (TTM) $0 $0 Nuvation Bio Inc.
Earnings per Share (Diluted) $-0.60 $-1.44 Nuvation Bio Inc.
Beta (Stock Volatility) 1.61 1.01 Recursion Pharmaceuticals Inc.
Short % of Float 23.23% 34.94% Nuvation Bio Inc.

Nuvation Bio Inc. vs Recursion Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

NUVB
RXRX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nuvation Bio Inc.-3.67%-0.42%7.03%8.26%-43.61%-44.99%
Recursion Pharmaceuticals Inc.-3.88%9.46%-1.42%-1.98%-25.54%-17.38%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nuvation Bio Inc.125.47%179.53%-60.98%-51.96%-51.96%-51.96%
Recursion Pharmaceuticals Inc.-14.11%-56.38%-87.80%-88.53%-88.53%-88.53%

Performance & Financial Health Analysis: Nuvation Bio Inc. vs Recursion Pharmaceuticals Inc.

MetricNUVBRXRX
Market Information
Market Cap i$1.75B$1.85B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i2,882,97711,402,630
90 Day Avg. Volume i3,312,78212,390,473
Last Close$4.72$3.47
52 Week Range$1.57 - $9.75$2.77 - $7.18
% from 52W High-51.59%-51.67%
All-Time High$15.23 (May 24, 2021)$42.81 (Jul 12, 2021)
% from All-Time High-69.01%-91.89%
Growth Metrics
Quarterly Revenue Growth6.33%6.82%
Quarterly Earnings Growth6.33%6.84%
Financial Health
Profit Margin (TTM) i0.85%0.04%
Operating Margin (TTM) i-0.81%-3.29%
Return on Equity (TTM) i-0.53%-0.60%
Debt to Equity (MRQ) i21.906.89
Cash & Liquidity
Book Value per Share (MRQ)$0.88$2.14
Cash per Share (MRQ)$1.52$1.41
Operating Cash Flow (TTM) i$-173,427,008$-371,808,000
Levered Free Cash Flow (TTM) i$-115,776,248$-208,521,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nuvation Bio Inc. vs Recursion Pharmaceuticals Inc.

MetricNUVB (Apr 24, 2026)RXRX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-2.44
Forward P/E i-35.31-4.12
PEG Ratio i-35.310.04
Price to Sales (TTM) i28.3024.83
Price to Book (MRQ) i5.811.64
Market Capitalization
Market Capitalization i$1.75B$1.85B
Enterprise Value i$1.32B$1.19B
Enterprise Value Metrics
Enterprise to Revenue i20.9415.88
Enterprise to EBITDA i-6.23-2.10
Risk & Other Metrics
Beta i1.611.01
Book Value per Share (MRQ) i$0.88$2.14

Financial Statements Comparison: Nuvation Bio Inc. vs Recursion Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNUVB (2025)RXRX (2025)
Revenue/Sales i62.90M74.26M
Cost of Goods Sold i9.30M70.95M
COGS % of Revenue i14.8%95.6%
Gross Profit i53.60M3.30M
Gross Margin i85.2%4.4%
Research & Development i115.11M475.27M
Operating Income (EBIT) i-213.06M-648.13M
Operating Margin i-338.7%-872.8%
EBITDA i-188.37M-559.38M
EBITDA Margin i-299.5%-753.3%
Pre-Tax Income i-204.63M-644.90M
Pre-Tax Income % of Revenue i-325.3%-868.5%
Income Tax i0-136,000
Income Tax % of Revenue i0.0%-0.2%
Net Income (Profit) i-204.63M-644.76M
Profit Margin i-325.3%-868.3%

Balance Sheet & Liquidity Metrics

MetricNUVB (2025)RXRX (2025)
Cash & Equivalents i164.09M743.29M
Total Current Assets i571.52M812.85M
Total Current Assets % of Revenue i908.6%1,094.7%
Total Current Liabilities i82.23M147.71M
Total Current Liabilities % of Revenue i130.7%198.9%
Long-Term Debt i49.75M56.21M
Long-Term Debt % of Revenue i79.1%75.7%
Total Shareholders Equity i305.72M1.13B
Retained Earnings i-1.12B-2.08B
Retained Earnings % of Revenue i-1,773.2%-2,795.7%
Property, Plant & Equipment i3.92M158.71M

Cash Flow Statement Comparison

MetricNUVB (2025)RXRX (2025)
Operating Cash Flow i-175.98M-422.39M
Operating Cash Flow % of Revenue i-279.8%-568.8%
Capital Expenditures i-354,000-6.47M
Free Cash Flow i-181.78M-380.44M
FCF Margin i-289.0%-512.3%
Debt Repayment i-11.90M-8.43M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNUVBRXRX
Shares Short i48.73M174.40M
Short Ratio i9.6214.00
Short % of Float i23.23%34.94%
Shares Outstanding i346.50M528.18M
Float Shares i237.04M510.29M
% Held by Insiders i18.67%2.85%
% Held by Institutions i62.24%64.60%
% Held by Public i19.09%32.55%

Dividend Analysis & Yield Comparison: Nuvation Bio Inc. vs Recursion Pharmaceuticals Inc.

MetricNUVBRXRX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A